Published in Science on February 05, 1999
Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS). Proc Natl Acad Sci U S A (1999) 4.37
Genomics of Actinobacteria: tracing the evolutionary history of an ancient phylum. Microbiol Mol Biol Rev (2007) 4.13
Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med (2005) 4.00
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2003) 3.70
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A (2004) 3.52
Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother (2007) 3.41
Comparing genomes within the species Mycobacterium tuberculosis. Genome Res (2001) 3.40
A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun (2000) 3.27
Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res (2008) 3.26
Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis (2010) 2.98
How to become a uropathogen: comparative genomic analysis of extraintestinal pathogenic Escherichia coli strains. Proc Natl Acad Sci U S A (2006) 2.75
Aquatic plants stimulate the growth of and biofilm formation by Mycobacterium ulcerans in axenic culture and harbor these bacteria in the environment. Appl Environ Microbiol (2004) 2.59
Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol (2000) 2.59
Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis (2007) 2.56
Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proc Natl Acad Sci U S A (2002) 2.41
Distribution of Mycobacterium ulcerans in buruli ulcer endemic and non-endemic aquatic sites in Ghana. PLoS Negl Trop Dis (2008) 2.16
Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun (2003) 2.08
Genotyping Mycobacterium ulcerans and Mycobacterium marinum by using mycobacterial interspersed repetitive units. J Bacteriol (2005) 2.06
First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis (2008) 1.93
Globally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone F. Infect Immun (2006) 1.91
Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother (2001) 1.90
Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis (2003) 1.84
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. PLoS Pathog (2007) 1.83
Immune response to infection with Mycobacterium ulcerans. Infect Immun (2001) 1.82
Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol (2009) 1.77
A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxin. Infect Immun (2005) 1.73
Development and application of real-time PCR assay for quantification of Mycobacterium ulcerans DNA. J Clin Microbiol (2003) 1.72
Infection with Mycobacterium ulcerans induces persistent inflammatory responses in mice. Infect Immun (2005) 1.59
Biosynthesis of polyketides in heterologous hosts. Microbiol Mol Biol Rev (2001) 1.55
Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans. J Bacteriol (2005) 1.55
Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun (2002) 1.54
Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob Agents Chemother (2003) 1.54
Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg Infect Dis (2007) 1.53
Whole genome comparisons suggest random distribution of Mycobacterium ulcerans genotypes in a Buruli ulcer endemic region of Ghana. PLoS Negl Trop Dis (2015) 1.51
Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis (2011) 1.51
Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer. Infect Immun (2001) 1.50
Necrosis of lung epithelial cells during infection with Mycobacterium tuberculosis is preceded by cell permeation. Infect Immun (2000) 1.48
Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med (2007) 1.48
Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun (2004) 1.48
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. PLoS Med (2007) 1.47
Evidence for an intramacrophage growth phase of Mycobacterium ulcerans. Infect Immun (2006) 1.45
Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol (2014) 1.44
Molecular epidemiologic evaluation of transmissibility and virulence of Mycobacterium tuberculosis. J Clin Microbiol (1999) 1.43
Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon. PLoS Negl Trop Dis (2013) 1.42
Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis (2007) 1.40
Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun (2007) 1.40
Mycobacterium tuberculosis arrests host cycle at the G1/S transition to establish long term infection. PLoS Pathog (2017) 1.38
Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect Immun (2001) 1.35
Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun (2004) 1.34
Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep (2008) 1.32
The phosphopantetheinyl transferases: catalysis of a post-translational modification crucial for life. Nat Prod Rep (2014) 1.32
Detection of Mycobacterium ulcerans in the environment predicts prevalence of Buruli ulcer in Benin. PLoS Negl Trop Dis (2012) 1.27
Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis (2008) 1.27
Use of the immunodominant 18-kiloDalton small heat shock protein as a serological marker for exposure to Mycobacterium ulcerans. Clin Vaccine Immunol (2006) 1.26
Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife? Future Microbiol (2011) 1.20
Subtractive hybridization reveals a type I polyketide synthase locus specific to Mycobacterium ulcerans. J Bacteriol (2003) 1.15
The local immune response in ulcerative lesions of Buruli disease. Clin Exp Immunol (2006) 1.13
Persistent association of Mycobacterium ulcerans with West African predaceous insects of the family belostomatidae. Appl Environ Microbiol (2008) 1.11
Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue. PLoS Negl Trop Dis (2010) 1.11
Buruli ulcer, Central African Republic. Emerg Infect Dis (2010) 1.10
Secondary bacterial infections of buruli ulcer lesions before and after chemotherapy with streptomycin and rifampicin. PLoS Negl Trop Dis (2013) 1.10
Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol (2002) 1.08
Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis (2010) 1.08
Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob Agents Chemother (2010) 1.08
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis (2011) 1.07
Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (buruli ulcer) in a murine study. Infect Immun (2008) 1.06
Interaction of Mycobacterium ulcerans with mosquito species: implications for transmission and trophic relationships. Appl Environ Microbiol (2010) 1.05
Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (2009) 1.05
The pathogenic mechanism of the Mycobacterium ulcerans virulence factor, mycolactone, depends on blockade of protein translocation into the ER. PLoS Pathog (2014) 1.05
Deciphering the genetic basis for polyketide variation among mycobacteria producing mycolactones. BMC Genomics (2008) 1.04
Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest (2013) 1.04
Necrotic death of Rhodococcus equi-infected macrophages is regulated by virulence-associated plasmids. Infect Immun (2004) 1.03
A novel mycolactone toxin obtained by biosynthetic engineering. Chembiochem (2007) 1.02
Nerve damage in Mycobacterium ulcerans-infected mice: probable cause of painlessness in buruli ulcer. Am J Pathol (2006) 1.02
Buruli ulcer: the third most common mycobacterial infection. CMAJ (2002) 1.01
Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother (2010) 1.01
Large sequence polymorphisms unveil the phylogenetic relationship of environmental and pathogenic mycobacteria related to Mycobacterium ulcerans. Appl Environ Microbiol (2009) 1.00
Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis (2009) 1.00
Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun (2010) 1.00
CHEMICAL AND MINERALOGICAL CHARACTERISTICS OF FRENCH GREEN CLAYS USED FOR HEALING. Clays Clay Miner (2008) 1.00
Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring. PLoS Negl Trop Dis (2011) 0.99
Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clin Vaccine Immunol (2008) 0.99
BCG-mediated protection against Mycobacterium ulcerans infection in the mouse. PLoS Negl Trop Dis (2011) 0.98
Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection. Antimicrob Agents Chemother (2010) 0.98
Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis (2013) 0.98
Insertion sequence element single nucleotide polymorphism typing provides insights into the population structure and evolution of Mycobacterium ulcerans across Africa. Appl Environ Microbiol (2013) 0.98
"Mycobacterium ulcerans subsp. shinshuense" isolated from a skin ulcer lesion: identification based on 16S rRNA gene sequencing. J Clin Microbiol (2007) 0.98
Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease. BMC Infect Dis (2014) 0.98
Detection of Mycobacterium ulcerans by the loop mediated isothermal amplification method. PLoS Negl Trop Dis (2012) 0.96
Lipid synthesis in protozoan parasites: a comparison between kinetoplastids and apicomplexans. Prog Lipid Res (2013) 0.96
Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer. PLoS Negl Trop Dis (2009) 0.95
Structural and functional cellular changes induced by Burkholderia pseudomallei rhamnolipid. Infect Immun (2003) 0.95
Mycobacterium ulcerans fails to infect through skin abrasions in a guinea pig infection model: implications for transmission. PLoS Negl Trop Dis (2014) 0.92
Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination. PLoS One (2012) 0.92
A synthetic entry to pladienolide B and FD-895. Bioorg Med Chem Lett (2007) 0.92
Local and regional re-establishment of cellular immunity during curative antibiotherapy of murine Mycobacterium ulcerans infection. PLoS One (2012) 0.92
A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice. Infect Immun (2007) 0.91
Analysis of Mycobacterium species for the presence of a macrolide toxin, mycolactone. Infect Immun (2004) 0.91
Associations between Mycobacterium ulcerans and aquatic plant communities of West Africa: implications for Buruli ulcer disease. Ecohealth (2014) 0.90
Phage therapy is effective against infection by Mycobacterium ulcerans in a murine footpad model. PLoS Negl Trop Dis (2013) 0.90
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: a randomised trial. Lancet (1999) 6.69
Guided medication dosing for inpatients with renal insufficiency. JAMA (2001) 6.25
CD1-restricted T cell recognition of microbial lipoglycan antigens. Science (1995) 5.03
Facial fractures and submental tracheal intubation. Anaesthesia (2002) 4.13
The Australian Incident Monitoring Study. Crisis management--validation of an algorithm by analysis of 2000 incident reports. Anaesth Intensive Care (1993) 4.04
Comparison of the ability of enteroinvasive Escherichia coli, Salmonella typhimurium, Yersinia pseudotuberculosis, and Yersinia enterocolitica to enter and replicate within HEp-2 cells. Infect Immun (1987) 3.81
Acid and base resistance in Escherichia coli and Shigella flexneri: role of rpoS and growth pH. J Bacteriol (1994) 3.81
An STS-based radiation hybrid map of the human genome. Genome Res (1997) 3.57
Intracellular trafficking in Mycobacterium tuberculosis and Mycobacterium avium-infected macrophages. J Immunol (1994) 3.55
Acid resistance in enteric bacteria. Infect Immun (1993) 3.53
A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun (2000) 3.27
Mycobacterium ulcerans infection on Phillip Island, Victoria. Med J Aust (1994) 3.12
Variability in 3' end of 16S rRNA sequence of Mycobacterium ulcerans is related to geographic origin of isolates. J Clin Microbiol (1996) 3.07
Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J Immunol (1992) 3.03
Effect of RF coil excitation on field inhomogeneity at ultra high fields: a field optimized TEM resonator. Magn Reson Imaging (2001) 2.84
Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha-subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the gsalpha gene. Proc Natl Acad Sci U S A (1998) 2.71
Trafficking and release of mycobacterial lipids from infected macrophages. Traffic (2000) 2.65
Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA-DNA hybridization, and 16S rRNA gene sequence analysis. J Clin Microbiol (1998) 2.58
Helios, a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin. Genes Dev (1998) 2.37
Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol (2001) 2.36
The mouse c-abl locus: molecular cloning and characterization. Cell (1984) 2.33
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Adductor tenotomies in children with quadriplegic cerebral palsy: longer term follow-up. J Pediatr Orthop (2000) 2.21
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Mice lacking major histocompatibility complex class I and class II molecules. Proc Natl Acad Sci U S A (1993) 2.18
Intensive cataract training: a novel approach. Eye (Lond) (2013) 2.17
N-cadherin regulates target specificity in the Drosophila visual system. Neuron (2001) 2.16
CD1c restricts responses of mycobacteria-specific T cells. Evidence for antigen presentation by a second member of the human CD1 family. J Immunol (1996) 2.13
Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis (2008) 2.12
The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol (1999) 2.03
Identification of sigma S-dependent genes associated with the stationary-phase acid-resistance phenotype of Shigella flexneri. Mol Microbiol (1996) 2.02
In vivo cytokine gene expression in T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse. Eur J Immunol (1990) 2.00
Access to data: comparing AccessMed with Query by Review. J Am Med Inform Assoc (1996) 1.98
Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl Acad Sci U S A (2004) 1.98
Comparison of DNA probes and the Sereny test for identification of invasive Shigella and Escherichia coli strains. J Clin Microbiol (1986) 1.96
Sequence of reovirus haemagglutinin predicts a coiled-coil structure. Nature (1985) 1.95
Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infect Immun (1998) 1.93
The pathology of Mycobacterium ulcerans infection. Pathology (1985) 1.90
Analysis of the murine All-1 gene reveals conserved domains with human ALL-1 and identifies a motif shared with DNA methyltransferases. Proc Natl Acad Sci U S A (1993) 1.89
The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci U S A (1993) 1.86
Macrophage activation: lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early genes c-fos, KC, JE, and tumor necrosis factor-alpha. J Immunol (1993) 1.78
Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol (2000) 1.78
Cloning and expression of a smooth muscle caldesmon. J Biol Chem (1989) 1.74
Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis (2003) 1.74
Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol (1998) 1.73
Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology (2000) 1.71
Host restriction phenotypes of Salmonella typhi and Salmonella gallinarum. Infect Immun (1995) 1.67
Osteoclasts express high levels of pp60c-src in association with intracellular membranes. J Cell Biol (1992) 1.67
Acute airway management in the critically ill child requiring transport. Can J Anaesth (1991) 1.63
Molecular interaction of CD1b with lipoglycan antigens. Immunity (1998) 1.60
Dielectric resonances and B(1) field inhomogeneity in UHFMRI: computational analysis and experimental findings. Magn Reson Imaging (2001) 1.60
Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene (2001) 1.58
Differential trafficking of live and dead Mycobacterium marinum organisms in macrophages. Infect Immun (1997) 1.58
Carbohydrate metabolism in lactic streptococci: fate of galactose supplied in free or disaccharide form. Appl Microbiol (1973) 1.57
Inpatient emergencies encountered by an infectious disease consultative service. Clin Infect Dis (1998) 1.56
Tumor necrosis factor production in patients with leprosy. Infect Immun (1992) 1.55
The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol (2001) 1.54
Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese. Eur J Neurol (2009) 1.54
Colonic polyps in an unselected population: prevalence, characteristics, and associations. Am J Gastroenterol (1994) 1.53
Paternal versus maternal transmission of a stimulatory G-protein alpha subunit knockout produces opposite effects on energy metabolism. J Clin Invest (2000) 1.51
Ethyl-substituted erythromycin derivatives produced by directed metabolic engineering. Proc Natl Acad Sci U S A (1998) 1.50
Inositol phosphate capping of the nonreducing termini of lipoarabinomannan from rapidly growing strains of Mycobacterium. J Biol Chem (1995) 1.50
Epidemiology and diagnosis of Mycobacterium tuberculosis in captive Asian elephants (Elephas maximus). J Zoo Wildl Med (2001) 1.49
Medical management of a large aortic thrombus in a young woman with essential thrombocythemia. Mayo Clin Proc (2001) 1.49
Attenuation of ischemic liver injury by monoclonal anti-endothelin antibody, AwETN40. J Am Coll Surg (1997) 1.47
Jugular venous bulb catheterization in infants and children. Crit Care Med (1989) 1.47
A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. J Bone Miner Res (1999) 1.47
The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. J Biol Chem (2001) 1.46
Clinical features of Mycobacterium ulcerans infection. Australas J Dermatol (1985) 1.46
Identification and macrophage-activating activity of glycolipids released from intracellular Mycobacterium bovis BCG. Mol Microbiol (2003) 1.45
Characterization of the acid resistance phenotype and rpoS alleles of shiga-like toxin-producing Escherichia coli. Infect Immun (1996) 1.44
Mycobacterial glycolipids: isolation, structures, antigenicity, and synthesis of neoantigens. Methods Enzymol (1989) 1.43
Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther (2003) 1.42
Overdose with chloral hydrate: a pharmacological and therapeutic review. Med J Aust (1989) 1.42
The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg (1998) 1.42
Disease management. Decreasing cost and increasing patient satisfaction: the implementation of a cancer disease management program. Manag Care Interface (1999) 1.40
Theoretical model for an MRI radio frequency resonator. IEEE Trans Biomed Eng (2000) 1.40
Acid-sensitive enteric pathogens are protected from killing under extremely acidic conditions of pH 2.5 when they are inoculated onto certain solid food sources. Appl Environ Microbiol (1998) 1.40
The experience of nausea during sustained hyper-gravity flight with negligible angular velocity. Aviat Space Environ Med (2000) 1.40
Pediatric and neonatal critical care transport: a comparison of therapeutic interventions. Pediatr Emerg Care (1996) 1.39
Strategies to inhibit alloantibody production in alloprimed murine recipients of hematopoietic stem cell grafts. Am J Transplant (2015) 1.39
UHG-based mutation screening in type 2B von Willebrand's disease: detection of a candidate mutation Ser547Phe. Thromb Haemost (1996) 1.39
CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus. J Virol (1999) 1.39
Structural definition of acylated phosphatidylinositol mannosides from Mycobacterium tuberculosis: definition of a common anchor for lipomannan and lipoarabinomannan. Glycobiology (1995) 1.38
Structure and antigenicity of lipoarabinomannan from Mycobacterium bovis BCG. J Gen Microbiol (1993) 1.38
The identification of Mycobacterium marinum genes differentially expressed in macrophage phagosomes using promoter fusions to green fluorescent protein. Mol Microbiol (1998) 1.37
Cryoablation of ventricular tachycardia guided by return cycle mapping after entrainment. J Thorac Cardiovasc Surg (2001) 1.37
Innexins: a family of invertebrate gap-junction proteins. Trends Genet (1998) 1.36
Acute and chronic alcohol dose: population differences in behavior and neurochemistry of zebrafish. Genes Brain Behav (2009) 1.36
Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect Immun (2001) 1.35
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res (2001) 1.34
The pimB gene of Mycobacterium tuberculosis encodes a mannosyltransferase involved in lipoarabinomannan biosynthesis. J Biol Chem (1999) 1.33
Expression of the core lipopeptide of the glycopeptidolipid surface antigens in rough mutants of Mycobacterium avium. J Biol Chem (1993) 1.31
Isolation and functional comparison of bovine cardiac troponin T isoforms. J Biol Chem (1987) 1.29
Parathyroid hormone-related protein: immunohistochemical localization in cancers and in normal skin. J Bone Miner Res (1989) 1.28
Identification and recombinant expression of a Mycobacterium avium rhamnosyltransferase gene (rtfA) involved in glycopeptidolipid biosynthesis. J Bacteriol (1998) 1.27
A randomized, controlled clinical trial of a treatment for shoulder pain. Phys Ther (1997) 1.27
Complete structure of the mycolactones. J Am Chem Soc (2001) 1.27